Progres in the treatment of patients with small solitary abode; squalid lung cancer (SCLC) has be due [i]or[/i] owing in two phases.

Progres in the treatment of patients with small solitary abode; squalid lung cancer (SCLC) has be due [i]or[/i] owing in two phases. In the first phase, SCLC was recognized, level when seemingly localized to the lung and intrathoracic lymph nodes, to be widely metastatic and to require effective systemic therapy from the opening The development of active chemotherapeutic agents and combinations in the 1970 improved median survival from the 6 month seen with radiotherapy alone to about 1 year. In the secondary phase has come the recognition that local rule of a disease, even undivided with systemic spread, is necessary for its help This has resulted both in a better appreciation of the part of radiation therapy in SCLC treatment and in efforts to optimize combined-morality regimens using radiotherapy and chemotherapy. With in every one's mouth treatment regimens involving concurrent or closely interdigitated administration of cisplatin and etoposide chemotherapy and radiation doses of 45 Gy given throughout 3 to 5 weeks, median survivals of 20 to 24 month have been reported by dint of many single institutions and confirmed in large cooperative cluster trials. Issues remaining to be resolv include optimization of radiation dose, convolution and timing; the role of prophylactic cranial irradiation; and to what extent to reduce acute and late toxic reactions of treatment. As we bring out more specific therapies based upon specific molecular and biological characteristics of SCLC including its autocrine extension regulation, we will be challenged to integrate these prosperously with current radiation and chemotherapeutic approaches. (CHEST 1998; 113:92S-100S)

Small confined apartment lung cancer (SCLC) makes up about 20% of all lung cancer eases diagnosed in North America. Since the 1960 SCLC has been recognized to differ the two biologically and clinically from other lung cancer histologic patterns Biologically, SCLC is more commonly associated with expression of neuroendocrine markers like neuron-specific enolase and chromogranin, and with the demeanor of dense core granules onward electron microscopy. Paraneoplastic syndromes, as it was as the syndrome of inappropriate (secretion of) antidiuretic hormone and hyperadrenocorticism, be met with more frequently with SCLC than with other histologic patterns Clinically, patients with SCLC were noted almost not to present with early stage (T1-2N0M0) disease unless almost invariably had hilar and mediastinal lymph node metastases, and in about pair thirds, metastasis beyond the thorax could be demonstrated (using 1970 imaging technology) at the time of diagnosis. plane in patients with apparently regional disease, local surgery and/or radiotherapy were rarely curative ([is les than] 5% survival at 5 years), culminating in greatest in number eases in the early and fatal appearance of systemic disease. This grim biological behavior was partly counterbalanced by the agency of the observation that SCLC is more responsive to one as well as the other radiation therapy and a variety of chemotherapeutic agents, including allcylating agents, vinca alkaloids, and antimetabolites, than are other lung cancer histologic representations The 1970s showed marked improvements in SCLC treatment eventuates with median survival of patients with disease limited to the thorax improving from about 6 month to 1 year and about 10% of patients surviving prolonged term (up from [is les than] 5%)[1] However, despite impressive early rejoinder rates to therapy, most patients rapidly died of refractory disease that appeared in systemic sites.

Several factors discloseed in the 1980s and confirmed in cooperative collection trials in the early 1990 have changed this apparent plateau in treatment issue Current SCLC treatment approaches can yield median survivals of 90 to 24 month 2-year survival rates in the range of 40% and 5-year survival rates of about 20%2 These improvements have be due [i]or[/i] owing from the following developments: (1) improved diagnostic radiology the couple for staging (which has produc about artifactual improvement in survival because of stage migration) and delineation of compass of disease for planning radiation therapy; (2) a better understanding of required radiation therapy doses and target contortions and exploitation of altered fractionation schemes; (3) progress to maturity of chemotherapy that is the two more effective and better capable of being combined with radiation therapy with manageable (albeit oftentimes significant) toxic reactions; and (4) the recognition according to Oncologists that SCLC is neither a local nor a systemic disease still both and that optimization of treatment requires not the optimization of radiotherapy or chemotherapy moreover of their combined use. In the following sections, I will focus forward combined-modality therapy employing radiotherapy and chemotherapy from the perspective of radiation Oncology; other contributors in this issue will address the chemotherapeutic aspects of this approach.

ISSUES IN SCLC STAGING

Comparison of different SCLC treatment series has been complicated by means of the variability of staging schemes used and changes in staging technology from one side of to the other time. While the TNM (tumor node metastases) staging classification has had reasonably good prognostic value for other lung cancer histologic archetypes at least those treated surgically, it has not been used widely in SCLC where the vast majority of patients have stage IIIA, IIIB, or IV disease. Instead, staging has been dichotomized to those patients without detectable disease outside the chest (said to have limited disease) and those with demonstrable extrathoracic or extensive disease. Since patients with "limited" disease treated barely with locoregional therapies typically fail rapidly in distant sites, it is likely that patients are being divided simply by dint of the bulk of their extrathoracic disease. More sensitive means of SCLC detection (eg CT scan v radionuclide scan of the liver and brain or monoclonal antibody staining of bone marrow biopsy specimens) have dearly increased the proportion of patients staged as having extensive disease. This stage migration has, in move round probably improved the survival issues for patients with both limited and extensive disease independent of any authentic improvements in the efficacy of therapy.[3] Further complicating matters is the fact that several conditions in SCLC (eg vicinity of pleural effusions, supraclavicular nodes, or contralateral hilar nodes) have been considered limited disease in more [i]or[/i] less trials and extensive disease in others. a certain quantity of studies have used the genuinely operational definition that limited disease is what can be encompassed in a "reasonable" radiotherapy portal, assuming (quite incorrectly) that radiotherapists have defined an standard for reasonable portals. calm though imaging approaches have plateaued and staging definitions have become more uniform in novel years, these past differences should be kept in mind when the eventuates obtained by different institutions and cooperative disposes are compared.

...